Drug Trial Radar · NCT07767110
Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- NanOlogy, LLC (doing business as Intryx Therapeutics, LLC)Industry
- Sponsor type
- Industry
- Collaborators
- WEP Clinical
- First posted
- Aug 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-label, dose-escalating, Phase 1/2a trial of Large Surface Area Microparticle (LSAM)-Cisplatin (development code ITX-402) to treat participants with diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG), via stereotactic infusion under intraoperative magnetic resonance imaging (MRI) guidance.
Conditions
- Diffuse Midline Glioma (DMG)
- Diffuse Intrinsic Pontine Glioma (DIPG)
- Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
Interventions
LSAM-CisplatinDrug
Participants with diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG), will receive a single intratumoral infusion of LSAM-Cisplatin 6 mg/mL via MRI-guided delivery at an infusion rate of 5 µL/min. Phase 1 (Dose Escalation): Participants will be enrolled sequentially into one of six dose levels. Volumes being delivered will range from 25 to 275 µL over a time period of 5 to 55 minutes. Phase 2 (Dose Expansion): Participants will receive LSAM-Cisplatin 6 mg/mL at the recommended Phase 2 dose (RP2D) selected based on the safety and tolerability findings from the dose-escalation phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability)Time frame: Day 1 to Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.